Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

m.

Merck forward-looking statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

Prescribing information and patient product information for JANUVIA and JANUMET are attached.

JANUVIA(TM) and JANUMET(TM) are trademarks of Merck & Co., Inc. -0-

JANUVIA(TM)(sitagliptin) Tablets                     9762701


    HIGHLIGHTS OF PRESCRIBING INFORMATION


    These highlights do not include all the information needed to use

JANUVIA safely and effectively. See full prescribing information for

JANUVIA.


    JANUVIA(TM) (sitagliptin) Tablets


    Initial U.S. Approval: 2006


    INDICATIONS AND USAGE


    JANUVIA is indicated as an adjunct to diet and exercise to improve

glycemic control in patients with type 2 diabetes mellitus (type 2

diabetes). JANUVIA is indicated for:


    --  Monotherapy (1.1)


    --  Combination therapy with metformin or a peroxisome

        proliferator-activated receptor ga
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/27/2015)... 27, 2015  Virginia Women,s Center is adding a ... health issues often caused by menopause. The MonaLisa, an ... anesthesia, received FDA clearance in 2014. ... practices in Virginia to offer ... to help postmenopausal women as well as breast cancer ...
(Date:5/27/2015)... , May 27, 2015  With Freudenberg ... a unique service: machined seals from the ... The seals, that have the same material ... original Freudenberg-NOK series products, can be made-to-order ... cost-effective small production runs. The agenda is ...
(Date:5/27/2015)...  The 2015 LiftWalker, developed by the medical ... ball drive actuator to give the wheelchair-bound untapped ... largest selection of electromechanical linear actuators custom made ... including medical devices. Ideomotion develops ... well as people who just need assistance in ...
Breaking Medicine Technology:Virginia Women's Center Welcomes The Newest Breakthrough In Women's Health Treatment 2Virginia Women's Center Welcomes The Newest Breakthrough In Women's Health Treatment 3Xpress Service from Freudenberg-NOK Quickly Delivers Made-to-Order Sealing Solutions to Customers 2Innovative Technology Liberates the Wheelchair-Bound 2
...   Delcath Systems, Inc. (NASDAQ: DCTH ) ... Board. "As a widely respected hepatologist ... (ILCA), Dr. Gores will contribute a wealth of clinical ... our Medical Advisory Board," said Eamonn P. Hobbs, CEO ...
... PLEASANTON, Calif., Dec. 21, 2011  TriReme Medical, Inc. ... the treatment of complex vascular disease, announced today ... U.S. Food and Drug Administration to market its ... of occluded peripheral arteries. Chocolate was developed in ...
Cached Medicine Technology:Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4TriReme Medical, Inc. Receives FDA 510(K) Clearance for Chocolate PTA Balloon Catheter 2
(Date:5/27/2015)... Rock, AR (PRWEB) May 27, 2015 ... Medix today announce a partnership to provide CMSA's ... Medix community. This collaboration seeks to strengthen the ... measurement through CMSA’s CKP program. The mutually beneficial ... on identifying individual skills of talent in the ...
(Date:5/27/2015)... Mountain View, CA (PRWEB) May 27, 2015 ... Napa Valley will be able to reach for Organic Coconut ... 2015. Coco Libre will be available at VIP areas, artist ... will also be available at area hotels and on festival ... as a partner this year,” said Noa Elan, Director of ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
(Date:5/27/2015)... 27, 2015 SmarterSkin, http://www.smarterskindermatology.com , is ... cutting-edge test that makes it easier for patients to find ... , Dr. Sejal Shah is a cosmetic dermatologist based ... to offer the test. This revolutionary DNA test uses 16 ... skin aging: , 1. Firmness and elasticity , ...
(Date:5/27/2015)... CRN International, the radio marketing and promotions ... Financial Officer. , Prinner most recently was Principal of ... financial/operational executive positions at telecom and technology services companies ... and SNET. His accounting and consulting career began ... will be able to tap into his experience of ...
Breaking Medicine News(10 mins):Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2Health News:CRN International Names New Chief Financial Officer 2
... ... ... continuing to offer H1N1 nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) ... sites in Huntley, Woodstock, Crystal Lake and McHenry and will be open as follows: , ...
... , LA JOLLA, Calif., Dec. 3 ... Studies unanimously voted to elect three new members during its ... is co-founder and Managing Director of De Novo Ventures in Palo ... in early stage medical device and biotechnology companies. Dotzler founded Medicus ...
... , Research could lead to an ... known to result in cancer and genetic diseases , ... first time observed the movement of a single molecule of ... significantly, they have identified a previously unknown step that they ...
... primates , , THURSDAY, Dec. 3 (HealthDay News) -- A ... a primate study. , The drug, called SPC3649, uses a ... Unlike other antivirals that target the virus itself, the new ... that hepatitis C needs to replicate, the researchers explained. , ...
... , , CHICAGO, Dec. 3 ... medicine, called platelet-rich plasma therapy (PRP), is showing strong ... to a prominent dental researcher and editor of the ... James Rutkowski, DMD, PhD, reported at the recent annual ...
... Deutsches rzteblatt International contains the first scientific presentation ... virus (H1N1/09) in the German-speaking countries since the start ... the Dsseldorf University Hospital retrospectively evaluated data from a ... Dtsch Arztebl Int 2009; 106[47]: 770-6). Their medical-scientific ...
Cached Medicine News:Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: